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Abstract Atrophic facial acne scarring is a widely pre-
valent condition that can have a negative impact on a
patient’s quality of life. The appearance of these scars is
often worsened by the normal effects of aging. A number of
options are available for the treatment of acne scarring,
including chemical peeling, dermabrasion, ablative or
nonablative laser resurfacing, dermal ﬁllers, and surgical
techniques such as subcision or punch excision. Depending
on the type and extent of scarring, a multimodal approach is
generally necessary to provide satisfactory results. Resur-
facing techniques correct surface irregularities, long-lasting
dermal ﬁllers address the volume loss resulting from acne,
and sub-superﬁcial musculoaponeurotic system (SMAS)
face-lift procedures counter the soft tissue laxity and ptosis
associated with aging. This article brieﬂy reviews the evo-
lution of individual approaches to treating atrophic acne
scarring, followed by case examples illustrating results that
can be achieved using a multimodal approach. Represen-
tative cases from patients in their 30s, 40s, and 50s are
presented. In the author’s clinical practice, multimodal
approaches incorporating fractionated laser, injectable
poly-L-lactic acid, and sub-SMAS face-lift procedures have
achieved optimal aesthetic outcomes, high patient satis-
faction, and durability of aesthetic effect over time.
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Acneisoneofthemostcommonskinconditionsexperienced
by adolescents and adults. Reported prevalence rates vary
from 35% to more than 90% in adolescents [1], while a
community-based study in adults aged[25 years reported
overall prevalence rates of 54% in women and 40% in men
[2].InamorerecentsurveyofadultsagedC20 years,73.3%
reported ever having acne, and rates of current acne were
higher in women than in men across different age groups,
from50.9%/42.5%(women/men)inthoseaged20–29 years
to 15.3%/7.3% in those aged C50 years [3]. In a study of
patients selected from acne clinics, at least some degree of
facial scarring was identiﬁed in 95% of cases [4]. Acne
scarringcanbedeeplydistressing topatients, often resulting
in decreasedself-esteem and a diminished quality of life [5].
Unfortunately, acne scarring also can be a difﬁcult
problem to address satisfactorily, usually requiring the use
of several different treatment modalities over multiple
treatment sessions [6–8]. The challenge stems in part from
the variability of scars in each individual patient and from
patient to patient. Depending on the degree of acne-
induced inﬂammation and atrophic effects, individual scars
can vary widely in type, depth, and extent, with different
scars requiring different treatment approaches [6]. Com-
pounding the problem, many of the established treatment
approaches for acne scarring have been associated with
substantial morbidity and recuperation time [6, 9]. A fur-
ther challenge stems from the fact that facial aging often
exacerbates the effects of acne scarring. Inﬂammation
associated with moderate to severe acne can result in der-
mal collagen and fat loss, leading to atrophic scarring [8].
Similarly, aging itself is associated with fat loss, magni-
fying the effects of acne scarring. When facial skin begins
to sag as a natural consequence of aging, it becomes sus-
pended on old ﬁbrotic acne scars. This tends to produce
an irregular cascading appearance. Thus, patients with
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their 30s, 40s, or 50s, as age begins to worsen the
appearance of the scarring [9].
This article brieﬂy discusses the physiological changes
associated with atrophic acne scars and the aging face, and
reviews the evolution of treatment modalities for this
patient population. Case examples from the author’s
practice will be used to illustrate a multimodal treatment
approach that have been successful in treating acne scar-
ring and aging face for patients of different age groups.
This approach generally combines laser resurfacing, poly-
L-lactic acid (PLLA) injection, and sub-superﬁcial muscu-
loaponeurotic system (SMAS) face-lift procedures.
Overview of Acne Scarring
Types of acne scars include keloid, hypertrophic, and
atrophic. Atrophic acne scarring is by far the most common
form, especially on the face [6]. Atrophic acne scars can be
broadly categorized as rolling, ice-pick, shallow boxcar, or
deep boxcar (Table 1)[ 10, 11]. Histologically, atrophic
acne scars exhibit thinning of the skin and loss of collagen,
elastin, and deep dermal fat resulting in a downward pull of
the epidermis [12]. In the case of deep cystic acne lesions,
inﬂammatory mediators destroy facial fat while the size of
the lesion itself can leave a void after its involution that
cannot be ﬁlled by surrounding subcutaneous tissues.
Rather, the tissues may be drawn in from surface layers, an
effect worsened by the contracture of the scarring around
the cysts. In such cases, a patient’s appearance can actually
worsen after the cystic acne is brought under control by
isotretinoin or other successful treatments [6].
Treatment Options for Management of Atrophic Acne
Scarring
Because of the varying types and severity of acne scarring,
it is important to keep in mind that the management of
scarring in any individual patient will likely require some
combination of techniques: resurfacing techniques to
address superﬁcial irregularities; dermal ﬁllers to replace
lost volume in large atrophic areas; surgical procedures
such as punch excision to remove deep boxcar or large ice-
pick scars; and face-lift procedures to restore facial shape
and tighten the skin in older patients in whom facial aging
is magnifying the effects of acne scarring. Figure 1 illus-
trates the effects of facial aging on acne scars. Figure 1a
was taken at age 46 with mild acne scarring visible on the
cheek and temple. Figure 1b is the same patient 10 years
later. The laxity of skin due to aging is apparent and the
acne scarring has become more prominent. Figure 1c was
taken 4 months after a face-lift with simultaneous subder-
mal injection of 1 vial of injectable PLLA (Sculptra
,
Dermik Laboratories, Bridgewater, NJ) to each side of the
face. In this series of photographs, no resurfacing proce-
dures were performed. As discussed in additional detail in
the Dermal Filler subsection, it is this author’s preference
to use injectable PLLA (prepared and injected as descri-
bed) as the dermal ﬁller of choice to treat acne scarring in
the aging face. The preparation of injectable PLLA
involves reconstituting each vial of product with 8 ml of
normal saline (without lidocaine) and allowing at least 24 h
but less than 72 h for complete product hydration before
use. Injectable PLLA is injected in a grid-like pattern into
the subdermal and deep dermal planes during a face-lift
procedure, with greater volume injected into areas with the
greatest lipoatrophy. Post procedure massage is not per-
formed over the treated area.
Resurfacing Techniques
Historically, acne scarring has been treated by chemical
peeling for superﬁcial scars and dermabrasion for deeper
scars [13]. The application of trichloroacetic acid (TCA) to
the skin causes epidermal cellular necrosis and necrosis of
collagen in the papillary to upper reticular dermis,
depending on the concentration of TCA. Following a TCA
peel, the skin reepithelializes during the next several days
Table 1 Global acne scarring classiﬁcation: type of scars making up the classiﬁcation grades
Grade Level of
disease
Example of scars
1 Macular Erythematous, hyper-, or hypo pigmented ﬂat marks; a problem of color rather than contour; visible to the patient or
observer at any distance
2 Mild Mild rolling, small soft papular; may not be obvious at social distances of C50 cm; may be covered adequately by
makeup or shadow of shaved beard hair in men
3 Moderate More signiﬁcant rolling, shallow boxcar, mild to moderate hypertrophic or papular scars; obvious at social distances of
50 cm, not easily covered, able to be ﬂattened by manual stretching of the skin (if atrophic)
4 Severe Punched out atrophic (deep boxcar), ice pick, bridges and tunnels, marked atrophy, dystrophic signiﬁcant hypertrophy or
keloid; obvious at social distances, not easily covered, and not able to be ﬂattened by manual stretching of the skin
Reprinted with permission from [9]
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months [12, 14]. This technique has been reﬁned for
treatment of atrophic acne scars using the Chemical
Reconstruction Of Skin Scars (CROSS) method, which
employs focal application of high-concentration TCA (65
or 100%) [12, 15]. The CROSS method is reported to
produce improved clinical results with rapid healing time
and lower complication rates [14]. Dermabrasion tech-
niques also have been reﬁned over the years, evolving from
the use of sandpaper to mechanical devices such as serrated
wheels or diamond-embedded fraises that deliver steady,
even abrasion; however, they remain very operator-
dependent [6].
Even with these innovations, mechanical and chemical
ablative techniques have largely been overtaken by ablative
or nonablative laser techniques for resurfacing, which are
technically easier to perform and tend to produce less
variable results [6]. Ablative laser skin resurfacing for
atrophic acne scars has been performed successfully with
far-infrared CO2 or erbium:yttrium-aluminum-garnet laser
systems. These methods selectively target water-containing
tissue of the epidermis and dermis, causing reproducible
degrees of skin vaporization and stimulating wound
remodeling with new collagen and elastin formation
[16, 17]. While CO2 lasers are very effective in treating
acne scarring, they are also the most operator-dependent of
the newer generation of ablative methods and techniques
vary based on personal experience [10]. Fully ablative
resurfacing techniques are often associated with swelling,
burning discomfort, oozing, and crusting of the face, as
well as signiﬁcant downtime (1–2 weeks) for the patient.
There is also a risk of prolonged postoperative erythema
after initial healing (lasting weeks or months), permanent
hypopigmentation, infection, and occasionally ﬁbrosis and
scarring [16–18]. Due to these potential complications,
patients are becoming less willing to choose fully ablative
laser therapy, and these techniques are now giving way to
nonablative or partially ablative laser therapies that stim-
ulate collagen remodeling while minimally disrupting the
epidermis.
The ﬁrst method shown to induce dermal ﬁbroblasts to
produce new collagen without damaging the epidermis
employed a 585-nm pulsed dye laser (PDL) that targeted
hemoglobin to create a thermal insult to the dermal
microvasculature [17, 19]. Postoperative purpura persisting
for several days has somewhat limited the usefulness of
PDL in treating acne scarring [17]. Newer nonablative laser
or light-based systems include the 1064- and 1320-nm
neodymium-doped (Nd):YAG, 1450-nm diode, and
1540-nm erbium glass lasers, and intense pulsed light
systems [18]. These techniques combine epidermal surface
cooling with longer wavelengths that penetrate to the der-
mal layer to create a controlled thermal injury. In small
studies of the 1064-nm Nd:YAG laser for the treatment of
atrophic scars, most patients showed mild to moderate
clinical improvement with signiﬁcant increases in the
number and density of collagen ﬁbers; adverse events were
limited to mild transient erythema and increased skin
Fig. 1 a Mild acne scarring in a
46-year-old woman. b Same
patient 10 years later
(age = 56) illustrating the
effects of facial aging and acne
scarring. c Four months after a
face-lift procedure with
simultaneous subdermal
placement of injectable PLLA
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123sensitivity [20, 21]. In a similar study comparing the
1320-nm Nd:YAG and 1450-nm diode lasers, it was found
that both of these methods were similarly effective and
associated with mild to moderate clinical improvements in
atrophic acne scarring [17].
Fractional photothermolysis is a further innovation in
resurfacing technique that was developed in response to the
safety concerns of full ablative therapies and the modest
efﬁcacy results demonstrated for the nonablative therapies
discussed above [18, 22]. This technique is based on the
creation of spatially precise microscopic thermal zones
(MTZs) at depths of 200–500 lm and spaced at
200–300 lm intervals, leaving surrounding tissue intact
[18]. It was ﬁrst described using a 1550-nm erbium ﬁber
laser (Fraxel
, Solta Medical Inc., Hayward, CA), although
other fractional laser devices are now available [22]. This
method differs from other resurfacing techniques in that
damaged epidermal components are extruded by viable
keratinocytes at the lateral margins of the MTZs and
exfoliated after several days (lending the skin a bronzed
appearance), epidermal tissue that is spared between ther-
mal zones contains viable cells capable of rapid reepi-
thelialization, and the stratum corneum remains intact
immediately after treatment due to its low water content.
The gradual exfoliation of the epidermis following frac-
tional resurfacing also results in improved superﬁcial
dyspigmentation. This technique generally requires a series
of three to six treatments at 2–4 week intervals for best
clinical improvement, which can achieve results for
atrophic scars similar to that of traditional ablative laser
skin resurfacing. In contrast to ablative techniques, adverse
effects are typically mild and transient, including erythema,
periocular edema, and a slight bronzing of the skin [18].
Dermal Fillers
The goal of using dermal ﬁllers in the treatment of atrophic
acne scarring is to replace volume lost by the atrophic
effects of the acne. As such, the ideal agent would be one
that restores volume to the defect by stimulating the sur-
rounding tissue to replace collagen for a long-lasting effect,
as opposed to those that provide a short-term effect based
on the volume of injected resorbable material. Based on the
experience of the author and other published sources,
injectable collagens and many of the available hyaluronic
acid (HA) preparations are too short-lived (approximately
3-6 months [10, 23]) to appropriately treat moderate to
severe acne scars, and use of such products for this purpose
would require a signiﬁcant total injection volume over time
with frequent retreatments, contributing to greater total
cost and time commitment for the patient. Less viscous
forms of HA, such as Restylane
 (Medicis Aesthetics,
Scottsdale, AZ) or Juvederm
 (Allergan, Santa Barbara,
CA), may be appropriate for patients with mild atrophic
scars [9].
Autologous fat transplantation has been proven suc-
cessful in the treatment of acne scarring, and has the
advantage of complete biocompatibility [24]. Grafted fat
has the potential for long-term correction if it is handled
atraumatically and the proper harvesting/grafting technique
is followed, but it also has proved unpredictable in the
hands of many surgeons [24]. Many factors are involved in
the survival of autologous fat, such as harvest site selection
and technique, recipient site and injection technique,
methods of processing, temperature and duration of fat
storage, and patient age [25]. Other potential disadvantages
of this treatment modality include unpredictable subdermal
placement and creation of a second surgical site to harvest
the fat.
Longer-acting dermal ﬁllers have the advantage of
predictably longer persistence and may be appropriate for
larger areas characteristic of rolling scars. Calcium
hydroxylapatite and injectable PLLA are two longer-acting
products that have published information on their use
for atrophic acne scarring. Calcium hydroxylapatite
(Radiesse
, BioForm Medical, San Mateo, CA) was eval-
uated in a single-center, prospective, controlled trial of ten
patients with acne scarring (including at least one saucer-
ized scar) [26]. At the 12-month evaluation, three patients
showed [75% improvement and six patients experienced
50–75% improvement in treated saucerized scars; one
patient had 25–50% improvement in this type of scar. No
patients showed improvement in ice-pick scars. Due to the
shorter persistence of the product relative to injectable
PLLA, the author does not use calcium hydroxylapatite in
the multimodal approach to treating acne scarring that is
described here.
Injectable PLLA was originally approved by the Food
and Drug Administration for the treatment of lipoatrophy
associated with treatment using highly active antiretroviral
therapy (HAART) for human immunodeﬁciency virus
infection. The results achieved with injectable PLLA in
HAART-associated lipoatrophy led to its use in treating
lipoatrophy associated with aging and acne scarring [27].
Although injectable PLLA has not been approved for
treatment of acne scarring in the US, it is now approved for
use in immune-competent people as a single regimen
for correction of shallow to deep nasolabial fold contour
deﬁciencies and other facial wrinkles [28]. Clinical beneﬁts
of injectable PLLA have been reported to persist for two
years or longer [27, 29, 30]. Injectable PLLA has been
studied in a single-center, open-label, prospective study
conducted in 20 patients with facial scars resulting from
moderate to severe acne or varicella [31]. In this study, the
investigator reported signiﬁcant reductions in severity of
scars treated with injectable PLLA over the course of seven
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reached a maximum of 46.4% (p\0.0001). The author of
this study speculated that injectable PLLA corrected the
acne scars by both subcision, in which the injection method
severed the ﬁbrous bands that tether the skin downward,
and by stimulating collagen production, which pushes the
skin upward. Injectable PLLA worked best for scars that
were at least as broad as they were deep, and were no more
than 2–3 mm deep, rather than small ice-pick scars.
Two recent case reports have further supported the
clinical beneﬁts associated with injectable PLLA for the
treatment of atrophic acne scars [7, 8]. In a report on two
female patients who each underwent three treatment ses-
sions with injectable PLLA, both were extremely pleased
with their results at 1- and 4-year follow-up evaluations [8].
In an additional report of a 60-year-old woman who had
previously failed to achieve satisfactory results from CO2
laser resurfacing, dermabrasion, TCA peels, collagen, cal-
cium hydroxylapatite, and HA dermal ﬁllers, the patient
noted observable improvements in her acne scars 6 months
after her seventh treatment session with injectable PLLA
[7]. This patient experienced minimal swelling (up to
3 days) and injection-site bruising (up to 7 days); inject-
able PLLA was well tolerated throughout the course of her
treatment [7].
Surgical Options
Subcision and punch excision remain important surgical
options for certain types of atrophic acne scars. Subcision,
which can be useful in combination therapy for moderate
levels of scarring, appears to work by breaking up the
attachments of these scars under the skin and releasing the
surface from deeper structures [9]. Punch techniques
remain the gold standard for large, deep boxcar and ice-
pick scars [9].
In addition to the direct treatments for acne scarring
discussed in the preceding sections, face-lift procedures can
be a valuable component of a multimodal approach to acne
scarring—especially in patients approaching their fourth
decade or older—by addressing the effects of facial aging
that serve to magnify the appearance of the scars. Among
other changes that occur with age, the diffuse and balanced
distribution of superﬁcial and deep fat that characterizes the
youthful face is lost; soft tissue fullness is lost in certain
areas, while persistence or hypertrophy of fat occurs in
others. Face-lift procedures generally aim to restore the
balanced distribution of facial fullness seen in youth, but
conventional techniques utilize lifting and tightening to
counteract the facial soft-tissue descent rather than fully
addressing the issue of facial shape. Recently, however,
there has been an evolution away from conventional exci-
sion and suspension procedures toward the use of
conservative skin excision, deep fascial-SMAS manipula-
tion, and volume restoration [32]. Incorporation of SMAS
into face-lift procedures has represented a fundamental
change in facial rejuvenation surgery [33, 34], and one
advantage of this approach is that it avoids disruption of the
subcutaneous plane. Because the subcutaneous plane is not
disrupted, a dermal ﬁller can be injected at the time of the
face-lift procedure to provide soft tissue augmentation.
The face-lift technique favored by the author is a
modiﬁcation of the standard sub-SMAS operation, in
which undermining of the skin is initially limited to the
extent that the sub-SMAS plane can be entered and com-
plete release of the underlying ligamentous attachments
achieved. Elevation and ﬁxation of the SMAS composite
ﬂap to the zygomatic arch and deep temporal fascia allow
vertical repositioning of the malar fat pad. The skin is then
further released from the SMAS composite ﬂap, only to the
point of releasing any visible tethering points, such as those
resulting from acne scarring. The skin is redraped and
excess skin excised. After skin closure, injectable PLLA,
prepared according to the procedure described previously,
is injected into the deep subdermal plane to smooth the
irregular skin surface. Injectable PLLA is placed so that
deeper undulations of the skin receive a greater volume of
injected material than the surrounding rims of the scars.
While each of the described procedures used individu-
ally can produce very satisfactory results, especially in
younger patients with milder acne scarring, this author has
found that the combination of multiple modalities is often
necessary to optimize outcomes. The following case
examples illustrate the level of aesthetic correction that can
be achieved by a multimodal approach to acne scarring.
Each case example shows a patient in a different decade of
life.
Case Examples
Patients Aged 30-40 Years
In the 30-40-year-old patient, the atrophic component of
the scar is accentuated by early facial volume shifts and
subtle laxity of skin. This is more apparent in a thinner
patient because of the lower initial volume of facial fat
compared with that in an overweight patient. This case
example (Fig. 2a, b) shows a 40-year-old woman with
long-standing, grade 3 acne scarring who requested treat-
ment of the lower third of her face. Additionally, she
sought improvement in the overall quality of her skin. The
photographs on the left of each ﬁgure show the patient
during the initial evaluation before any procedures were
performed. The patient was seen again 2 months prior to
surgery, at which time two vials of injectable PLLA
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injected into the submalar cheeks and jawline for volume
restoration. A short-scar face-lift was performed in addition
to a platysmal corset with subplatysmal suprahyoid fascial
release and chin implant to achieve balance of her facial
proﬁle. Two vials of injectable PLLA were placed con-
comitantly with the face-lift. The injections were done in a
grid-like manner with greater amounts placed in the depths
of the atrophic scars. After 8 weeks, the patient was treated
with a nonablative erbium ﬁber laser (Fraxel Re:store
,
Solta Medical Inc.) for superﬁcial skin irregularities. The
postoperative photos on the right side of Fig. 2a and b were
taken 18 months after the procedures.
Patients Aged 40-50 Years
The next case example is a 46-year-old woman with long-
standing adult cystic acne that was unsuccessfully treated
with conservative measures, topical agents, and oral anti-
biotics, and ﬁnally controlled with a 12-month course of
isotretinoin. Several years after stabilization of the cystic
component of her acne, she presented with concerns related
to the grade 4 atrophic scars and facial aging (Fig. 3a, b).
The patient was treated with a short-scar face-lift with
concomitant injection of two vials of injectable PLLA
(prepared as described previously) placed in the subdermal
and deep dermal planes, with greater amounts placed in the
depths of each scar. Six months after the face-lift proce-
dure, she was treated with partial ablative resurfacing using
aC O 2 fractional laser (Lutronic USA, LLC, Princeton
Junction, NJ). The postoperative photos were taken
18 months after the face-lift procedure (1 year after laser
resurfacing).
Patients Aged 50-60 Years
The ﬁnal case example (Fig. 4a, b) is a 55-year-old woman
with long-standing, grade 3 and grade 4 acne scars after
treatment with isotretinoin for cystic acne many years
Fig. 2 a An example of a 30-40-year-old patient before (left) and
after (right) treatment with multiple modalities, including surgery,
dermal ﬁller, and nonablative laser. b A proﬁle view of the patient
before (left) and after (right) the procedures
Fig. 3 a An example of a 40–50-year-old patient with atrophic acne
scarring before (left) and after (right) multimodal treatment. b A4 5 
view of the patient before (left) and after (right) the procedures
1148 Aesth Plast Surg (2011) 35:1143–1150
123prior. She had a high lean body mass that accentuated the
appearance of her atrophic acne scars. Two sessions of
injectable PLLA (prepared as previously described) were
performed 24 months prior to the face-lift procedure to
address the facial lipoatrophy. A short-scar face-lift with
concomitant injection of an additional two vials of inject-
able PLLA was followed by four treatments with a non-
ablative erbium ﬁber laser (Fraxel Re:store
, Solta Medical
Inc.). The photographs on the right side of the ﬁgure show
the patient 20 months after the ﬁnal resurfacing procedure.
The combination of volume replacement, surgical reposi-
tioning, and resurfacing techniques led to an aesthetic
improvement and a high level of patient satisfaction.
Conclusions
Both acne scarring and the normal aging process can result
in the loss of dermal collagen and facial lipoatrophy, such
that patients already suffering from the negative impact of
facial acne scarring may ﬁnd the appearance of these scars
worsening over time as they approach their 40s and 50s.
Fortunately, treatment options for acne scarring have
evolved from solely mechanical or chemical resurfacing
techniques to multimodal approaches that can address
multiple aspects of the aesthetic defect. Particularly in the
aging face, optimal aesthetic outcomes can best be
achieved using a multimodal approach, including resur-
facing techniques to improve surface irregularities, long-
lasting dermal and subdermal ﬁllers to replace lost facial
volume, and face-lift procedures to reposition facial tissue.
To date there have not been published reports of other
multimodality treatment protocols for the treatment of the
constellation of ﬁndings in a patient with aging face and
atrophic acne. In the author’s clinical experience, the
combination of fractionated laser, injectable PLLA, and
sub-SMAS face-lift has produced outstanding results for
many patients with atrophic acne scarring in their third,
fourth, or ﬁfth decades.
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